At a glance
ClinicalIndex Comparison RecordN/ACompleted· 943 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy
In Brief
An observational study for Chemotherapy-induced Febrile Neutropenia. Completed, enrolled 943 participants across 74 sites in 9 countries.
Detailed Summary
To estimate the incidence of febrile neutropenia in patients with breast cancer and non-Hodgkin's lymphoma receiving high (\> 20%) FN-risk chemotherapy and pegfilgrastim primary prophylaxis.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsChemotherapy-induced Febrile Neutropenia
CountriesAustria, Belgium, Bulgaria, Czechia, France, Germany, Greece, Poland, Romania
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 2014
Enrollment StartJul 2014
Primary CompletionOct 2016
TodayJul 2026
First PostedJun 30, 2014
Enrollment StartJul 18, 2014
Primary CompletionOct 28, 2016
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 12.0 years ago